PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges

Vascular Pharmacology

Volumn 62, Issue 2, 2014, Pages 103-111

  Norata, Giuseppe Danilo ^a,b   Tibolla, Gianpaolo ^a,c   Catapano, Alberico Luigi ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b Bassini Hospital   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

Hypercholesterolemia; LDL cholesterol; LDL receptor; Monoclonal antibodies; PCSK9

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; ENZYME INHIBITION; GAIN OF FUNCTION MUTATION; GOLD STANDARD; HUMAN; HYPERCHOLESTEROLEMIA; HYPOCHOLESTEROLEMIA; LIVER CLEARANCE; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84904964617     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.05.011     Document Type: Review

References (92)

1. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478-3940.
2. Norata G.D., Ballantyne C.M., Catapano A.L. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J 2013, 34:1783-1789.
3. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
4. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
5. Tibolla G., Norata G.D., Artali R., Meneghetti F., Catapano A.L. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011, 21:835-843.
6. Dubuc G., Chamberland A., Wassef H., Davignon J., Seidah N.G., Bernier L., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24:1454-1459.
7. Rashid S., Curtis D.E., Garuti R., Anderson N.N., Bashmakov Y., Ho Y.K., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci U S A 2005, 102:5374-5379.
8. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., Kinch L., Grishin N.V., Horton J.D., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79:514-523.
9. Hooper A.J., Marais A.D., Tanyanyiwa D.M., Burnett J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007, 193:445-448.
10. Norata G.D., Tibolla G., Catapano A.L. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol 2014, 54:273-293.
11. Werner C., Hoffmann M.M., Winkler K., Bohm M., Laufs U. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol 2014, 62(2):94-102. (in this issue).
12. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100:928-933.
13. Benjannet S., Rhainds D., Essalmani R., Mayne J., Wickham L., Jin W., et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004, 279:48865-48875.
14. Hampton E.N., Knuth M.W., Li J., Harris J.L., Lesley S.A., Spraggon G. The self-inhibited structure of full-length PCSK9 at 1.9A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A 2007, 104:14604-14609.
15. Cunningham D., Danley D.E., Geoghegan K.F., Griffor M.C., Hawkins J.L., Subashi T.A., et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007, 14:413-419.
16. Qian Y.W., Schmidt R.J., Zhang Y., Chu S., Lin A., Wang H., et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007, 48:1488-1498.
17. Nassoury N., Blasiole D.A., Tebon Oler A., Benjannet S., Hamelin J., Poupon V., et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 2007, 8:718-732.
18. Lagace T.A., Curtis D.E., Garuti R., McNutt M.C., Park S.W., Prather H.B., et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006, 116:2995-3005.
19. Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007, 282:18602-18612.
20. Bottomley M.J., Cirillo A., Orsatti L., Ruggeri L., Fisher T.S., Santoro J.C., et al. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem 2009, 284:1313-1323.
21. Zhang D.W., Garuti R., Tang W.J., Cohen J.C., Hobbs H.H. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A 2008, 105:13045-13050.
22. Yamamoto T., Lu C., Ryan R.O. A two step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem 2011 Feb 18, 286(7):5464-5470.
23. Holla O.L., Cameron J., Tveten K., Strom T.B., Berge K.E., Laerdahl J.K., et al. Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors. J Lipid Res 2011, 52:1787-1794.
24. DeVay R.M., Shelton D.L., Liang H. Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J Biol Chem 2013, 288:10805-10818.
25. Chen X.W., Wang H., Bajaj K., Zhang P., Meng Z.X., Ma D., et al. SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. eLife 2013, 2:e00444.
26. Gustafsen C., Kjolby M., Nyegaard M., Mattheisen M., Lundhede J., Buttenschon H., et al. The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. Cell Metab 2014, 19:310-318.
27. Kosenko T., Golder M., Leblond G., Weng W., Lagace T.A. Low-density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated LDL receptor degradation. J Biol Chem 2013 Mar 22, 288(12):8279-8288.
28. Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 2013, 32:1585-1595.
29. Ferri N., Tibolla G., Pirillo A., Cipollone F., Mezzetti A., Pacia S., et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 2012, 220:381-386.
30. Rousselet E., Marcinkiewicz J., Kriz J., Zhou A., Hatten M.E., Prat A., et al. PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res 2011, 52:1383-1391.
31. Mayer G., Poirier S., Seidah N.G. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem 2008, 283:31791-31801.
32. Persson L., Cao G., Stahle L., Sjoberg B.G., Troutt J.S., Konrad R.J., et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 2010, 30:2666-2672.
33. Jeong H.J., Lee H.S., Kim K.S., Kim Y.K., Yoon D., Park S.W. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 2008, 49:399-409.
34. Essalmani R., Susan-Resiga D., Chamberland A., Abifadel M., Cremers J.W., Boileau C., et al. In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem 2011 Feb 11, 286(6):4257-4263.
35. Lipari M.T., Li W., Moran P., Kong-Beltran M., Sai T., Lai J., et al. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem 2012, 287:43482-43491.
36. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
37. Baass A., Dubuc G., Tremblay M., Delvin E.E., O'Loughlin J., Levy E., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
38. Cui Q., Ju X., Yang T., Zhang M., Tang W., Chen Q., et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010, 213:632-636.
39. Dubuc G., Tremblay M., Pare G., Jacques H., Hamelin J., Benjannet S., et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010, 51:140-149.
40. Awan Z., Seidah N.G., MacFadyen J.G., Benjannet S., Chasman D.I., Ridker P.M., et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 2012, 58:183-189.
41. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008, 49:394-398.
42. Welder G., Zineh I., Pacanowski M.A., Troutt J.S., Cao G., Konrad R.J. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010, 51:2714-2721.
43. Lambert G., Ancellin N., Charlton F., Comas D., Pilot J., Keech A., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54:1038-1045.
44. Troutt J.S., Alborn W.E., Cao G., Konrad R.J. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res 2010, 51:345-351.
45. Costet P., Hoffmann M.M., Cariou B., Guyomarc'h Delasalle B., Konrad T., Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010, 212:246-251.
46. Browning J.D., Horton J.D. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010, 51:3359-3363.
47. Persson L., Cao G., Stahle L., Sjoberg B., Troutt J.S., Konrad R.J., et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 2010 Dec, 30(12):2666-2672.
48. Levy E., Ouadda A.B., Spahis S., Sane A.T., Garofalo C., Grenier E., et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis 2013 Apr, 227(2):297-306.
49. Le May C., Kourimate S., Langhi C., Chetiveaux M., Jarry A., Comera C., et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 2009, 29:684-690.
50. Cariou B., Ouguerram K., Zair Y., Guerois R., Langhi C., Kourimate S., et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009, 29:2191-2197.
51. Cariou B., Langhi C., Le Bras M., Bortolotti M., Le KA Theytaz F., et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab (Lond) 2013, 10:4.
52. Sun X.M., Eden E.R., Tosi I., Neuwirth C.K., Wile D., Naoumova R.P., et al. Evidence for effect of mutant PCSK9 on apolipoprotein b secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet 2005, 14:1161-1169.
53. Herbert B., Patel D., Waddington S.N., Eden E.R., McAleenan A., Sun X.M., et al. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler Thromb Vasc Biol 2010, 30:1333-1339.
54. Ouguerram K., Chetiveaux M., Zair Y., Costet P., Abifadel M., Varret M., et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 2004, 24:1448-1453.
55. Lambert G., Jarnoux A.L., Pineau T., Pape O., Chetiveaux M., Laboisse C., et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 2006, 147:4985-4995.
56. Lalanne F., Lambert G., Amar M.J., Chetiveaux M., Zair Y., Jarnoux A.L., et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res 2005, 46:1312-1319.
57. Sullivan S., Fabbrini E., Horton J.D., Korenblat K., Patterson B.W., Klein S. Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people. Transl Res 2011, 158:302-306.
58. Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 2012, 32:1585-1595.
59. Brouwers M.C., van Greevenbroek M.M., Troutt J.S., Bonner Freeman A., Lu A., Schaper N.C., et al. Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia. Clin Sci 2011, 121:397-403.
60. Brouwers M.C., Konrad R.J., van Himbergen T.M., Isaacs A., Otokozawa S., Troutt J.S., et al. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia. Nutr Metab Cardiovasc Dis 2013, 23:1115-1121.
61. Langhi C., Le May C., Gmyr V., Vandewalle B., Kerr-Conte J., Krempf M., et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun 2009, 390:1288-1293.
62. Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J., Nassoury N., et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008, 283:2363-2372.
63. Canuel M., Sun X., Asselin M.C., Paramithiotis E., Prat A., Seidah N.G. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One 2013, 8:e64145.
64. Jonas M.C., Costantini C., Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep 2008, 9:916-922.
65. Labonte P., Begley S., Guevin C., Asselin M.C., Nassoury N., Mayer G., et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 2009, 50:17-24.
66. Lan H., Pang L., Smith M.M., Levitan D., Ding W., Liu L., et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells. J Cell Physiol 2010, 224:273-281.
67. Ranheim T., Mattingsdal M., Lindvall J.M., Holla O.L., Berge K.E., Kulseth M.A., et al. Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9. J Cell Physiol 2008, 217:459-467.
68. Roubtsova A., Munkonda M.N., Awan Z., Marcinkiewicz J., Chamberland A., Lazure C., et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 2011, 31:785-791.
69. Kwakernaak A.J., Lambert G., Dullaart R.P. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects. Clin Biochem 2012, 45:1522-1524.
70. Melone M., Wilsie L., Palyha O., Strack A., Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol 2012, 59:1697-1705.
71. Kysenius K., Muggalla P., Matlik K., Arumae U., Huttunen H.J. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell Mol Life Sci 2012, 69:1903-1916.
72. Casserly I.P., Topol E.J. Convergence of atherosclerosis and Alzheimer's disease: cholesterol, inflammation, and misfolded proteins. Discov Med 2004, 4:149-156.
73. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 2006, 103:5644-5651.
74. Norata G.D., Garlaschelli K., Grigore L., Raselli S., Tramontana S., Meneghetti F., et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010, 208:177-182.
75. Chen Y.Q., Troutt J.S., Konrad R.J. PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. Lipids 2014 May, 49(5):445-455.
76. Liu M., Wu G., Baysarowich J., Kavana M., Addona G.H., Bierilo K.K., et al. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J Lipid Res 2010, 51:2611-2618.
77. Postmus I., Trompet S., de Craen A.J., Buckley B.M., Ford I., Stott D.J., et al. PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. J Lipid Res 2012, 54:561-566.
78. Lillis A.P., Van Duyn L.B., Murphy-Ullrich J.E., Strickland D.K. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008, 88:887-918.
79. Boucher P., Gotthardt M., Li W.P., Anderson R.G., Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 2003, 300:329-332.
80. May P. The low-density lipoprotein receptor-related protein 1 in inflammation. Curr Opin Lipidol 2013, 24:134-137.
81. Hofmann S.M., Zhou L., Perez-Tilve D., Greer T., Grant E., Wancata L., et al. Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. J Clin Invest 2007, 117:3271-3282.
82. Denis M., Marcinkiewicz J., Zaid A., Gauthier D., Poirier S., Lazure C., et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 2012, 125:894-901.
83. Huijgen R., Fouchier S.W., Denoun M., Hutten B.A., Vissers M.N., Lambert G., et al. Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. J Lipid Res 2012, 53:979-983.
84. Lee C.J., Lee Y.H., Park S.W., Kim K.J., Park S., Youn J.C., et al. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism 2013 Jun, 62(6):845-850.
85. Finkelshtein D., Werman A., Novick D., Barak S., Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A 2013, 110:7306-7311.
86. Koren M.J., Lundqvist P., Bolognese M., Neutel J.M., Monsalvo M.L., Yang J., et al. Anti-PCSK9 monotherapy for hypercholesterolemia - the Mendel-2 randomized, controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014 Jun 17, 63(23):2531-2540.
87. Blom D.J., Hala T., Bolognese M., Lillestol M.J., Toth P.D., Burgess L., et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014 May 8, 370(19):1809-1819.
88. Stroes E., Colquhoun D., Sullivan D., Civeira F., Rosenson R.S., Watts G.F., et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014 Jun 17, 63(23):2541-2548.
89. Raal F.J., Giugliano R.P., Sabatine M.S., Koren M.J., Langslet G., Bays H., et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1300 patients in 4 phase II trials. J Am Coll Cardiol 2014, 63:1278-1288.
90. Rader D.J., Kastelein J.J. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 2014, 129:1022-1032.
91. Norata G.D., Tibolla G., Catapano A.L. Gene silencing approaches for the management of dyslipidaemia. Trends Pharmacol Sci 2013, 34:198-205.
92. Fitzgerald K., Frank-Kamenetsky M., Shulga-Morskaya S., Liebow A., Bettencourt B.R., Sutherland J.E., et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2013 Jan 4, 383(9911):60-68.